

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK API 33889 Insp GMP 33889/596852-0007

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :
Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : BASF PHARMA (CALLANISH) LIMITED

Site address : BASF PHARMA (CALLANISH) LIMITED, BREASCLETE, CALLANISH, ISLE OF LEWIS, HS2 9ED, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 29/11/2022 , it is considered that it complies with

- The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

-
- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
 - (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection :

- [1000002929] DOCOSAHEXAENOIC ACID
- [1000002806] EICOSAPENTAENOIC ACID

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

DOCOSAHEXAENOIC ACID

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
SMB purification / Flash Refining

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

SMB Refining Purification

3.5.2 Primary Packaging

Other : Material sensitive to oxidation must be stored under nitrogen blanket

3.5.3 Secondary Packaging

Other : Material sensitive to oxidation must be stored under nitrogen blanket

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

3.6.2 Microbiological testing (excluding sterility testing)

3.6.3 Microbiological testing (including sterility testing)

EICOSAPENTAENOIC ACID

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
SMB Purification / Flash refining

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

final refining & purification

3.5.2 Primary Packaging

Other : Material is sensitive to oxidation, must be kept under a gas blanket of oxygen free nitrogen.

3.5.3 Secondary Packaging

Other : Material is sensitive to oxidation, must be kept under a gas blanket of oxygen free nitrogen.

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

3.6.2 Microbiological testing (excluding sterility testing)

13/01/2023 Name and signature of the authorised person of the Competent Authority of United Kingdom
Confidential
Medicines and Healthcare products Regulatory Agency
Tel : Confidential

MHRA-GMDP

MHRA

MHRA-GMDP

MHRA